GlassScriptPhysician profile
Mohamed H Sadiq
NPI 1164410403
$13,592.34
in general payments reported to CMS, 2019-2025
63 companies · $3,145 in 2025
The $3,145 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $1,138 · 2021: $1,357 · 2022: $1,794 · 2023: $2,164 · 2024: $2,765 · 2025: $3,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,073.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,040.12 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,007.79 | 2021-2025 | Ubrelvy, Qulipta |
| Argenx US, INC. | $922.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $898.96 | 2019-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $885.49 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $771.96 | 2019-2025 | |
| Sk Life Science, INC. | $563.53 | 2020-2025 | Xcopri |
| Emd Serono, INC. | $560.00 | 2019-2025 | Evobrutinib, Mavenclad |
| Genzyme Corporation | $519.00 | 2019-2022 | |
| Lilly USA, LLC | $496.47 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $438.21 | 2020-2023 | Austedo Xr, Ajovy |
| Celgene Corporation | $435.36 | 2022-2024 | Zeposia |
| Neurelis, INC. | $403.85 | 2020-2025 | Valtoco |
| Tg Therapeutics, INC. | $283.07 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $276.49 | 2019-2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $257.02 | 2023-2025 | Hyqvia, Gammagard |
| Adamas Pharmaceuticals, INC. | $256.02 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $253.87 | 2020-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $228.26 | 2021-2022 | |
| Banner Life Sciences, LLC | $220.54 | 2021-2024 | |
| Csl Behring | $204.12 | 2019-2025 | Hizentra |
| Lundbeck LLC | $193.55 | 2019-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $187.60 | 2019-2025 | Rytary, Crexont |
| Amgen INC. | $170.00 | 2021-2023 | Aimovig |
| Genentech USA, INC. | $162.78 | 2019-2023 | Ocrevus, Enspryng |
| Eisai INC. | $160.79 | 2021-2025 | |
| Mdd US Operations, LLC | $145.90 | 2021-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $130.00 | 2019-2022 | |
| Tanabe Pharma America, INC. | $123.17 | 2019-2023 | |
| Pfizer INC. | $111.76 | 2024-2025 | |
| Livanova USA, INC. | $106.59 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $104.81 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $78.17 | 2021-2025 | Inbrija |
| E.R. Squibb & Sons, L.L.C. | $77.29 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $74.31 | 2022-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $68.80 | 2019-2024 | Gamunex-C |
| Cala Health, INC. | $62.71 | 2023-2025 | Cala Kiq, Cala Trio |
| Axsome Therapeutics, INC. | $54.18 | 2025 | Symbravo |
| Medtronic, INC. | $48.96 | 2025 | Intellis Adaptivestim |
| Allergan, INC. | $48.04 | 2020 | |
| Cycle Pharmaceuticals INC | $43.65 | 2025 | Tascenso Odt, Bafiertam |
| Acorda Therapeutics, INC | $41.99 | 2019-2024 | Inbrija, Ampyra |
| Averitas Pharma INC. | $41.06 | 2024 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $39.14 | 2021-2025 | |
| Avion Pharmaceuticals | $35.76 | 2022-2023 | Dhivy |
| Greenwich Biosciences, INC. | $34.38 | 2020 | |
| Vanda Pharmaceuticals INC. | $33.73 | 2024 | Ponvory |
| Xeris Pharmaceuticals, INC. | $29.27 | 2023-2024 | Keveyis |
| Boston Scientific Corporation | $26.28 | 2019 | |
| Janssen Biotech, INC. | $26.01 | 2025 | |
| Arbor Pharmaceuticals, INC. | $21.98 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.81 | 2025 | Rexulti |
| Aucta Pharmaceuticals, INC. | $21.50 | 2025 | Motpoly Xr |
| Braemar Manufacturing, LLC | $20.59 | 2019 | |
| Kyowa Kirin, INC. | $19.13 | 2024 | Nourianz |
| Jazz Pharmaceuticals INC. | $17.57 | 2025 | |
| Avanir Pharmaceuticals, INC. | $16.80 | 2022 | |
| Akcea Therapeutics, INC. | $14.91 | 2020 | |
| Bio Products Laboratory USA, INC. | $14.76 | 2023 | Coagadex, Gammaplex |
| Inspire Medical Systems, INC. | $14.35 | 2024 | Inspire |
| Grt US Holding, INC. | $13.51 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.